ArticleBMJ open2026

Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial.

Masahiro Miyake et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.